Sponsored

Another milestone: Chimeric Therapeutics manufactures plasmids for clinical trial

Highlights

  • Chimeric Therapeutics has completed the manufacturing of CHM 2101 research-grade plasmids.
  • The achievement serves as a critical first step in developing CDH17 CAR T as CAR T therapies are dependent upon plasmids and viral vectors.
  • Chimeric is also progressing its CLTX CAR T Phase 1 clinical trial for glioblastoma, with patients at the City of Hope Cancer Centre now receiving second dose levels.

In a significant development, biotechnology company Chimeric Therapeutics (ASX:CHM) has successfully completed the manufacturing of CHM 2101 research-grade plasmids, which are small DNA molecules carrying genetic instructions.

The clinical-stage cell therapy company considers it to be a critical first step in developing CDH17 CAR (chimeric antigen receptor) T cell therapy as CAR T therapies are dependent upon plasmids and viral vectors, which hold genetic instructions for each specific CAR T product.

ALSO READ: Chimeric Therapeutics (ASX:CHM) to present clinical trial data at Global Neuro-Oncology Meeting

Notably, the CDH17 CAR T cell therapy, which targets oncogenic factor CDH17, is currently in pre-clinical development.

Chimeric plans to undertake the phase 1 clinical trial of CDH17 CAR T in 2022 in four tumour types – neuroendocrine, colorectal, pancreatic and gastric cancer.

ALSO READ: Crucial milestones and appointments: Chimeric Therapeutics (ASX:CHM) sees action-packed FY21

T-cell therapy, Chimeric Therapeutics

Source: CHM Website

Significant progress in CDH17 CAR T clinical trial

Chimeric, in collaboration with world-renowned cell therapy centre, the University of Pennsylvania, has completed and released all of the research grade helper and transfer plasmids for CDH17 CAR T.

In July this year, the Company obtained the exclusive licence to CDH17 CAR T cell therapy from the University of Pennsylvania. The CDH17 CAR T cell therapy is 3rd generation CAR T cell therapy.

The latest success enables progression to research vector manufacturing, GMP plasmid and vector manufacturing, and the advancement of technical operations, in line with the CDH17 CAR T phase 1 clinical trial.

What other developments are on the cards?

Meanwhile, Chimeric is also advancing its CLTX CAR T Phase 1 clinical trial for glioblastoma (brain cancer) at California-based City of Hope Cancer Centre, where CLTX CAR T was developed.

CLTX CAR T (CHM 1101) is an optimised first-in-class CAR T cell therapy which uniquely utilises Chlorotoxin (CLTX), a 36-amino acid peptide as its tumour targeting domain.

The Company has indicated that patients at The City of Hope Cancer Centre are now receiving second dose levels.

ALSO READ: Another feather in Chimeric Therapeutics’ cap, CLTX CAR technology secures EU patent

Management Comment

Chimeric’s CEO and Managing Director Jennifer Chow indicated that that the Company is very pleased to have been able to achieve this significant first step so rapidly after licensing.

Adding further, Chow said, “This accomplishment speaks to the commitment and drive that the Chimeric and University of Pennsylvania teams share to move this important CAR T forward to Phase 1 clinical trials.”

ALSO READ: Chimeric Therapeutics (ASX:CHM) adds three more experts to Cellular Immunotherapy Scientific Advisory Board

CHM shares were trading at AU$0.312 on 26 October (AEDT 11:29 AM), up 0.806% from its last close.

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK